|
1
|
Hohenstein P and Hastie ND: The many
facets of the Wilms’ tumour gene, WT1. Hum Mol Genet.
15:R196–R201. 2006.PubMed/NCBI
|
|
2
|
Rivera MN and Haber DA: Wilms’ tumour:
connecting tumorigenesis and organ development in the kidney. Nat
Rev Cancer. 5:699–712. 2005.
|
|
3
|
Pelletier J, Bruening W, Li FP, et al:
WT1 mutations contribute to abnormal genital system
development and hereditary Wilms’ tumour. Nature. 353:431–434.
1991. View
Article : Google Scholar
|
|
4
|
Brown KW, Wilmore HP, Watson JE, et al:
Low frequency of mutations in the WT1 coding region in Wilms’
tumor. Genes Chromosomes Cancer. 8:74–79. 1993.PubMed/NCBI
|
|
5
|
Wells J, Rivera MN, Kim WJ, Starbuck K and
Haber DA: The predominant WT1 isoform (+KTS) encodes a
DNA-binding protein targeting the planar cell polarity gene
Scribble in renal podocytes. Mol Cancer Res. 8:975–985.
2010.
|
|
6
|
Yang L, Han Y, Suarez Saiz F, Saurez Saiz
F and Minden MD: A tumor suppressor and oncogene: the WT1 story.
Leukemia. 21:868–876. 2007.PubMed/NCBI
|
|
7
|
Haber DA, Sohn RL, Buckler AJ and Housman
DE: Alternative splicing and genomic structure of the Wilms tumor
gene WT1. Proc Natl Acad Sci USA. 88:9618–9622. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klamt B, Koziell A, Poulat F, et al:
Frasier syndrome is caused by defective alternative splicing of
WT1 leading to an altered ratio of WT1 +/−KTS splice
isoforms. Hum Mol Genet. 7:709–714. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bor YC, Swartz J, Morrison A, Rekosh D,
Ladomery M and Hammarskjöld ML: The Wilms’ tumor 1 (WT1) gene (+KTS
isoform) functions with a CTE to enhance translation from an
unspliced RNA with a retained intron. Genes Dev. 20:1597–1608.
2006.
|
|
10
|
Hammes A, Guo JK, Lutsch G, et al: Two
splice variants of the Wilms’ tumor 1 gene have distinct functions
during sex determination and nephron formation. Cell. 106:319–329.
2001.
|
|
11
|
Lewis A and Reik W: How imprinting centres
work. Cytogenet Genome Res. 113:81–89. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hubertus J, Zitzmann F, Trippel F, et al:
Selective methylation of CpGs at regulatory binding sites controls
NNAT expression in Wilms tumors. PLoS One. 8:e676052013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Phillips JE and Corces VG: CTCF: master
weaver of the genome. Cell. 137:1194–1211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fiorentino FP and Giordano A: The tumor
suppressor role of CTCF. J Cell Physiol. 227:479–492. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jinno Y, Yun K, Nishiwaki K, et al: Mosaic
and polymorphic imprinting of the WT1 gene in humans. Nat Genet.
6:305–309. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mares J, Kríz V, Weinhäusel A, et al:
Methylation changes in promoter and enhancer regions of the WT1
gene in Wilms’ tumours. Cancer Lett. 166:165–171. 2001.PubMed/NCBI
|
|
17
|
Hancock AL, Brown KW, Moorwood K, et al: A
CTCF-binding silencer regulates the imprinted genes AWT1 and
WT1-AS and exhibits sequential epigenetic defects during
Wilms’ tumourigenesis. Hum Mol Genet. 16:343–354. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Kraker J, Graf N, van Tinteren H, et
al: Reduction of postoperative chemotherapy in children with stage
I intermediate-risk and anaplastic Wilms’ tumour (SIOP 93-01
trial): a randomised controlled trial. Lancet. 364:1229–1235.
2004.PubMed/NCBI
|
|
19
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Méreau A, Anquetil V, Cibois M, et al:
Analysis of splicing patterns by pyrosequencing. Nucleic Acids Res.
37:e1262009.
|
|
21
|
Burwell EA, McCarty GP, Simpson LA,
Thompson KA and Loeb DM: Isoforms of Wilms’ tumor suppressor gene
(WT1) have distinct effects on mammary epithelial cells. Oncogene.
26:3423–3430. 2007.
|
|
22
|
Hubertus J, Lacher M, Rottenkolber M,
Müller-Höcker J, Berger M, et al: Altered expression of imprinted
genes in Wilms tumors. Oncol Rep. 25:817–823. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mitsuya K, Sui H, Meguro M, Kugoh H, Jinno
Y, et al: Paternal expression of WT1 in human fibroblasts and
lymphocytes. Hum Mol Genet. 6:2243–2246. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Malik K and Brown KW: Epigenetic gene
deregulation in cancer. Br J Cancer. 83:1583–1588. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brown KW, Power F, Moore B, Charles AK and
Malik KT: Frequency and timing of loss of imprinting at 11p13 and
11p15 in Wilms’ tumor development. Mol Cancer Res. 6:1114–1123.
2008.PubMed/NCBI
|
|
26
|
Renda M, Baglivo I, Burgess-Beusse B,
Esposito S, Fattorusso R, et al: Critical DNA binding interactions
of the insulator protein CTCF: a small number of zinc fingers
mediate strong binding, and a single finger-DNA interaction
controls binding at imprinted loci. J Biol Chem. 282:33336–33345.
2007. View Article : Google Scholar
|
|
27
|
Xu X, Gammon MD, Zhang Y, Cho YH, Wetmur
JG, et al: Gene promoter methylation is associated with increased
mortality among women with breast cancer. Breast Cancer Res Treat.
121:685–692. 2010. View Article : Google Scholar : PubMed/NCBI
|
